Metopimazine Viatris Conseil

Metopimazine, the active ingredient in Metopimazine Viatris Conseil, is a phenothiazine derivative presented as an oral tablet for oral use. It reduces nausea and vomiting, including post‑operative nausea, in adult patients who require antiemetic therapy and is commonly prescribed in surgical and chemotherapy settings.

GNH USA supplies Metopimazine Viatris Conseil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable global logistics. Our distribution network ensures timely delivery to both established healthcare institutions and emerging markets.

Metopimazine is used as an antiemetic that blocks dopamine pathways involved in nausea and vomiting.

- Nausea: reduces the sensation of nausea and the frequency of vomiting episodes in adult patients. - Vomiting: controls episodes of vomiting associated with various triggers, improving patient comfort. - Post‑operative nausea and vomiting: prevents and treats nausea and vomiting after surgical procedures, aiding recovery.

Metopimazine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Drowsiness - Dry mouth - Constipation - Blurred vision - Orthostatic hypotension

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, akathisia) - Neuroleptic malignant syndrome - Severe hypotension or cardiac arrhythmias

Before prescribing Metopimazine, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess renal and hepatic function: adjust use in patients with severe impairment. - Avoid in patients with known hypersensitivity to phenothiazines. - Monitor for extrapyramidal symptoms: report any involuntary movements promptly. - Caution in elderly: increased risk of sedation and falls. - Review concomitant medications that affect dopamine pathways. - Store at room temperature: keep in the original container, protect from moisture and light.

Metopimazine can interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine blockade may cause severe extrapyramidal effects. - QT‑prolonging agents (e.g., quinidine): increased risk of cardiac arrhythmia. - CYP2D6 inhibitors (e.g., fluoxetine): may raise metopimazine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may enhance dry mouth and constipation. - Sedatives or CNS depressants: may increase drowsiness. - MAO inhibitors: potential for hypertensive crisis.